CD8A and neoplasm: Specifically, for the primary tumor, the percentage of CD8+ T cells in the total tumor cells significantly increased in both Hf12-DBA-mediated RT (2.92 ± 1.58 %) and Hf12-DBA-mediated RT plus anti-PD-L1-treated groups (2.42 ± 1.31%) compared to the PBS control group (0.67 ± 0.40%).